Hybio Pharmaceutical Co., Ltd. (SHE:300199)

Hybio Pharmaceutical Revenue

Hybio Pharmaceutical had revenue of 299.15M CNY in the quarter ending March 31, 2026, a decrease of -3.49%. This brings the company's revenue in the last twelve months to 955.53M, up 27.42% year-over-year. In the year 2025, Hybio Pharmaceutical had annual revenue of 966.35M with 63.73% growth.

• Revenue (ttm): 955.53M
• Revenue Growth: +27.42%
• P/S Ratio: 22.11
• Revenue / Employee: 923.22K
• Employees: 1,035
• Market Cap: 21.13B

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	966.35M	376.15M	63.73%
Dec 31, 2024	590.20M	158.81M	36.82%
Dec 31, 2023	431.38M	-272.94M	-38.75%
Jan 1, 2023	704.32M	-31.65M	-4.30%
Jan 1, 2022	735.97M	14.25M	1.97%

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

May 15, 2026

Data Sources Report a data error